PDSB

+ Watchlist + Portfolio

PDS Biotechnology Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.20
52-Week Range: $0.20 – $1.55
Market Cap: $11.69M
P/E (TTM): —
EPS (TTM): -0.67
Dividend Yield: —

Advanced Metrics

Price/Book: 1.24
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: —
Debt/Equity: 4.07
Total Debt: —
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: —

PDSB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$29.43M	$27.76M	$22.57M	$19.03M
Selling, General & Admin	$12.24M	$15.28M	$13.76M	$12.52M
Operating Expenses	$41.67M	$43.05M	$36.32M	$31.54M
Operating Income	-$41.67M	-$43.05M	-$36.32M	-$31.54M
EBITDA	-$40.74M	-$40.12M	-$33.79M	-$30.30M
Pretax Income	-$42.05M	-$44.35M	-$38.48M	-$35.67M
Income Tax	-$1.20M	-$1.41M	-$869.17K	-$1.17M
Net Income	-$40.85M	-$42.94M	-$37.61M	-$34.50M
Diluted EPS	-1.43	-1.39	-1.03	-0.74
Diluted Shares	28.60M	30.95M	36.45M	46.38M

PDSB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$73.82M	$56.56M	$41.69M	$26.71M
Current Assets	$76.48M	$59.06M	$45.05M	$28.25M
Total Assets	$77.01M	$59.39M	$45.36M	$30.49M
Current Liabilities	$9.82M	$13.63M	$17.09M	$9.48M
Long-Term Debt	$23.02M	$19.51M	$9.20M	$11.73M
Total Debt	$23.47M	$23.85M	$21.83M	$16.93M
Total Liabilities	$33.01M	$33.26M	$26.35M	$21.24M
Retained Earnings	-$101.56M	-$144.50M	-$182.11M	-$216.61M
Shareholders' Equity	$44.00M	$26.13M	$19.00M	$9.25M
Working Capital	$66.66M	$45.43M	$27.97M	$18.77M

PDSB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$25.71M	-$33.64M	-$35.03M	-$27.75M
Capital Expenditure	—	—	-$29.00K	—
Free Cash Flow	-$25.71M	-$33.64M	-$35.06M	-$27.75M
Depreciation & Amortisation	$86.00	$17.36K	$21.11K	$21.84K
Stock-Based Compensation	$5.20M	$7.61M	$6.85M	$4.11M
Investing Cash Flow	—	$0.00	-$29.00K	$0.00
Financing Cash Flow	$34.29M	$16.38M	$20.19M	$12.77M
Net Change in Cash	$8.58M	-$17.26M	-$14.87M	-$14.98M

PDSB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.83M	$4.21M	$4.58M	$4.41M	$3.46M
Selling, General & Admin	$3.27M	$3.41M	$3.56M	$2.27M	$3.06M
Operating Expenses	$9.11M	$7.62M	$8.14M	$6.67M	$6.52M
Operating Income	-$9.11M	-$7.62M	-$8.14M	-$6.67M	-$6.52M
EBITDA	-$8.72M	-$7.28M	-$7.85M	-$6.44M	-$6.33M
Pretax Income	-$9.66M	-$9.43M	-$9.01M	-$7.56M	-$7.35M
Income Tax	-$1.17M	$0.00	$0.00	$0.00	$0.00
Net Income	-$8.49M	-$9.43M	-$9.01M	-$7.56M	-$7.35M
Diluted EPS	-0.21	-0.21	-0.19	—	-0.13
Diluted Shares	40.52M	45.90M	46.87M	—	55.50M

PDSB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$39.98M	$31.87M	$26.20M	$26.71M	$21.66M
Current Assets	$42.47M	$33.65M	$27.89M	$28.25M	$22.89M
Total Assets	$47.03M	$40.48M	$34.71M	$30.49M	$24.66M
Current Liabilities	$18.27M	$11.53M	$13.33M	$9.48M	$10.15M
Long-Term Debt	$6.35M	$12.94M	$11.89M	$11.73M	$10.61M
Total Debt	$18.96M	$18.54M	$17.97M	$16.93M	$15.86M
Total Liabilities	$24.67M	$24.52M	$25.25M	$21.24M	$20.77M
Retained Earnings	-$190.60M	-$200.03M	-$209.04M	-$216.61M	-$223.96M
Shareholders' Equity	$22.36M	$15.96M	$9.45M	$9.25M	$3.89M
Working Capital	$24.20M	$22.12M	$14.56M	$18.77M	$12.74M

PDSB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.03M	-$9.10M	-$5.92M	-$3.70M	-$4.37M
Free Cash Flow	-$9.03M	-$9.10M	-$5.92M	-$3.70M	-$4.37M
Depreciation & Amortisation	$5.46K	$5.46K	$5.46K	$5.46K	$5.46K
Stock-Based Compensation	$1.25M	$448.03K	$1.25M	$1.16M	$1.16M
Investing Cash Flow	—	—	$0.00	$0.00	—
Financing Cash Flow	$7.32M	$995.94K	$241.21K	$4.22M	-$679.83K
Net Change in Cash	-$1.71M	-$8.11M	-$5.67M	$513.32K	-$5.05M

Market Snapshot

About

PDS Biotechnology is a clinical-stage immuno-oncology company developing therapies for cancer and infectious diseases. The company uses its proprietary Versamune T-cell activating platform to create cancer vaccines and immunotherapies. Lead programs target HPV-associated cancers and other solid tumors by activating immune responses against tumor-specific antigens.